CDK12 Changes Telling in Prostate Cancer
- PMID: 30006379
- DOI: 10.1158/2159-8290.CD-NB2018-093
CDK12 Changes Telling in Prostate Cancer
Abstract
A recent study established that patients with metastatic castration-resistant prostate cancer who had mutations that inactivated both CDK12 alleles also exhibited other genetic changes. Results of a small, related study suggest these genetic changes may make tumors more responsive to PD-1 inhibitors.
©2018 American Association for Cancer Research.
Comment on
-
Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer.Cell. 2018 Jun 14;173(7):1770-1782.e14. doi: 10.1016/j.cell.2018.04.034. Cell. 2018. PMID: 29906450 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
